Completed PHASE4 INTERVENTIONAL 2-arm NCT01386164

Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults (HIPAVAC)

Sponsor: Aarhus University Hospital

Updated 5 times since 2017 Last updated: Aug 15, 2013 Started: Aug 31, 2011 Primary completion: Dec 31, 2012 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01386164, this PHASE4 trial focuses on HIV and Human Papillomavirus and remains completed. Sponsored by Aarhus University Hospital, it has been updated 5 times since 2011, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aarhus University Hospital
University of Aarhus

Data source: University of Aarhus

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aarhus N, Denmark